Based on the Accolade Inc stock forecast from 10 analysts, the average analyst target price for Accolade Inc is USD 7.47 over the next 12 months. Accolade Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Accolade Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Accolade Inc’s stock price was USD 3.48. Accolade Inc’s stock price has changed by -0.29% over the past week, -2.25% over the past month and -67.84% over the last year.
No recent analyst target price found for Accolade Inc
No recent average analyst rating found for Accolade Inc
Company Overview Accolade Inc
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington. Read Less
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company off...Read More
Frequently Asked Questions About Accolade Inc (ACCD) Stock
Based on ratings from 10 analysts Accolade Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 10 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on ACCD's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for ACCD is USD 7.47 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 5.
ACCD stock's Price/Earning ratio is -99,999.99.
Our analysis grades ACCD stock's Price / Earning ratio at A+. This means that ACCD stock's Price/Earning ratio is above 0% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this ACCD may be undervalued for its sector.
The last closing price of ACCD's stock was USD 3.48.
The most recent market capitalization for ACCD is USD 0.30B.
Based on targets from 10 analysts, the average taret price for ACCD is projected at USD 7.47 over the next 12 months.
This means that ACCD's stock price may go up by +114.56% over the next 12 months.
We can't find any ETFs which contains Accolade Inc's stock.
As per our most recent records Accolade Inc has 2,400 Employees.
Accolade Inc's registered address is 1201 Third Avenue, Seattle, WA, United States, 98101.
You can get more information about it from Accolade Inc's website at https://www.accolade.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Accolade Inc (ACCD) Stock
Based on ratings from 10 analysts Accolade Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 10 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on ACCD's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for ACCD is USD 7.47 over the next 12 months. The maximum analyst target price is USD 13 while the minimum anlayst target price is USD 5.
ACCD stock's Price/Earning ratio is -99,999.99.
Our analysis grades ACCD stock's Price / Earning ratio at A+. This means that ACCD stock's Price/Earning ratio is above 0% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this ACCD may be undervalued for its sector.
The last closing price of ACCD's stock was USD 3.48.
The most recent market capitalization for ACCD is USD 0.30B.
Based on targets from 10 analysts, the average taret price for ACCD is projected at USD 7.47 over the next 12 months.
This means that ACCD's stock price may go up by +114.56% over the next 12 months.
We can't find any ETFs which contains Accolade Inc's stock.
As per our most recent records Accolade Inc has 2,400 Employees.
Accolade Inc's registered address is 1201 Third Avenue, Seattle, WA, United States, 98101.
You can get more information about it from Accolade Inc's website at https://www.accolade.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ACCD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
